Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells

Journal of Oncology

Volumn , Issue , 2009, Pages

  Simons, Andrean L ^a   Parsons, Arlene D ^a   Foster, Katherine A ^a   Orcutt, Kevin P ^a   Fath, Melissa A ^a   Spitz, Douglas R ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AURANOFIN; BUTHIONINE SULFOXIMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; PERIFOSINE; PROTEIN KINASE B; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL KILLING; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; ENZYME ACTIVITY; GLUTATHIONE METABOLISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN METABOLISM;

EID: 70349230931     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/519563     Document Type: Article

References (48)

1. Spitz D. R., Sim J. E., Ridnour L. A., Galoforo S. S., Lee Y. J., Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Annals of the New York Academy of Sciences 2000 899 349 362
2. Aykin-Burns N., Ahmad I. M., Zhu Y., Oberley L. W., Spitz D. R., Increased levels of superoxide and H 2 O 2 mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation Biochemical Journal 2009 418 1 29 37
3. Carew J. S., Huang P., Mitochondrial defects in cancer Molecular Cancer 2002 1 1 9
4. Pelicano H., Xu R.-H., Du M., Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism Journal of Cell Biology 2006 175 6 913 923
5. Brazil D. P., Hemmings B. A., Ten years of protein kinase B signalling: a hard Akt to follow Trends in Biochemical Sciences 2001 26 11 657 664
6. Song G., Ouyang G., Bao S., The activation of Akt/PKB signaling pathway and cell survival Journal of Cellular and Molecular Medicine 2005 9 1 59 71
7. Sun M., Wang G., Paciga J. E., AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells American Journal of Pathology 2001 159 2 431 437
8. Amornphimoltham P., Sriuranpong V., Patel V., Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 Clinical Cancer Research 2004 10 12 4029 4037
9. Konstantinov A. A., Peskin A. V., Popova E. Y., Khomutov G. B., Ruuge E. K., Superoxide generation by the respiratory chain of tumor mitochondria Biochimica et Biophysica Acta 1987 894 1 1 10
10. Szatrowski T. P., Nathan C. F., Production of large amounts of hydrogen peroxide by human tumor cells Cancer Research 1991 51 3 794 798
11. Toyokuni S., Okamoto K., Yodoi J., Hiai H., Persistent oxidative stress in cancer FEBS Letters 1995 358 1 1 3
12. Crul M., Rosing H., de Klerk G. J., Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours European Journal of Cancer 2002 38 12 1615 1621
13. Van Ummersen L., Binger K., Volkman J., A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer Clinical Cancer Research 2004 10 22 7450 7456
14. Bailey H. H., Mahoney M. R., Ettinger D. S., Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma Cancer 2006 107 10 2462 2467
15. Argiris A., Cohen E., Karrison T., A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer Cancer Biology and Therapy 2006 5 7 766 770
16. Knowling M., Blackstein M., Tozer R., A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial Investigational New Drugs 2006 24 5 435 439
17. Leighl N. B., Dent S., Clemons M., A phase 2 study of perifosine in advanced or metastatic breast cancer Breast Cancer Research and Treatment 2008 108 1 87 92
18. Hilgard P., Klenner T., Stekar J., Nssner G., Kutscher B., Engel J., D-21266, a new heterocyclic alkylphospholipid with antitumour activity European Journal of Cancer 1997 33 3 442 446
19. Maly K., Uberall F., Schubert C., Interference of new alkylphospholipid analogues with mitogenic signal transduction Anti-Cancer Drug Design 1995 10 5 411 425
20. Berkovic D., Cytotoxic etherphospholipid analogues General Pharmacology 1998 31 4 511 517 (Pubitemid 28458917)
21. Kondapaka S. B., Singh S. S., Dasmahapatra G. P., Sausville E. A., Roy K. K., Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Molecular Cancer Therapeutics 2003 2 11 1093 1103
22. Anderson M. E., Handbook of Methods for Oxygen Radical Research 1985 Boca Raton, Fla, USA CRC Press
23. Griffith O. W., Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine Analytical Biochemistry 1980 106 1 207 212
24. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., Protein measurement with the folin phenol reagent Journal of Biological Chemistry 1951 193 265 275
25. Spitz D. R., Malcolm R. R., Roberts R. J., Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in H 2 O 2 -resistant cell lines: do aldehydic by-products of lipid peroxidation contribute to oxidative stress? Biochemical Journal 1990 267 2 453 459
26. Holmgren A., Bjornstedt M., Thioredoxin and thioredoxin reductase Methods in Enzymology 1995 252 199 208
27. Schafer F. Q., Buettner G. R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple Free Radical Biology and Medicine 2001 30 11 1191 1212
28. Leleu X., Gay J., Roccaro A. M., Update on therapeutic options in Waldenstrm macroglobulinemia European Journal of Haematology 2009 82 1 1 12
29. Moral M., Paramio J. M., Akt pathway as a target for therapeutic intervention in HNSCC Histology and Histopathology 2008 23 10 1269 1278
30. Patel V., Lahusen T., Sy T., Sausville E. A., Gutkind J. S., Senderowicz A. M., Perifosine, a novel alkylphospholipid, induces p21WAF1 expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest Cancer Research 2002 62 5 1401 1409
31. Leslie N. R., Bennett D., Lindsay Y. E., Stewart H., Gray A., Downes C. P., Redox regulation of PI 3-kinase signalling via inactivation of PTEN EMBO Journal 2003 22 20 5501 5510
32. Leslie N. R., The redox regulation of PI 3-kinase-dependent signaling Antioxidants and Redox Signaling 2006 8 9-10 1765 1774
33. Kaneki M., Shimizu N., Yamada D., Chang K., Nitrosative stress and pathogenesis of insulin resistance Antioxidants and Redox Signaling 2007 9 3 319 329
34. Yasukawa T., Tokunaga E., Ota H., Sugita H., Martyn J. A. J., Kaneki M., S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance Journal of Biological Chemistry 2005 280 9 7511 7518
35. Spitz D. R., Kinter M. T., Roberts R. J., Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts Journal of Cellular Physiology 1995 165 3 600 609
36. Arrick B. A., Griffith O. W., Cerami A., Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis Journal of Experimental Medicine 1981 153 3 720 725
37. Andringa K. K., Coleman M. C., Aykin-Burns N., Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose Cancer Research 2006 66 3 1605 1610
38. Simons A. L., Ahmad I. M., Mattson D. M., Dornfeld K. J., Spitz D. R., 2-deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells Cancer Research 2007 67 7 3364 3370
39. Bailey H. H., L-S,R-buthionine sulfoximine: historical development and clinical issues Chemico-Biological Interactions 1998 111-112 239 254
40. Mustacich D., Powis G., Thioredoxin reductase Biochemical Journal 2007 346 1 8
41. Becker K., Gromer S., Schirmer R. H., Mller S., Thioredoxin reductase as a pathophysiological factor and drug target European Journal of Biochemistry 2000 267 20 6118 6125
42. Powis G., Kirkpatrick D. L., Angulo M., Baker A., Thioredoxin redox control of cell growth and death and the effects of inhibitors Chemico-Biological Interactions 1998 111-112 23 34
43. Smart D. K., Ortiz K. L., Mattson D., Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress Cancer Research 2004 64 18 6716 6724
44. Nguyen P., Awwad R. T., Smart D. D. K., Spitz D. R., Gius D., Thioredoxin reductase as a novel molecular target for cancer therapy Cancer Letters 2006 236 2 164 174
45. Shaw C. F. III, Gold-based therapeutics agents Chemical Review 1999 99 2589 2600
46. McKeage M. J., Maharaj L., Berners-Price S. J., Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria Coordination Chemistry Reviews 2002 232 1-2 127 135
47. Rigobello M. P., Folda A., Baldoin M. C., Scutari G., Bindoli A., Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase Free Radical Research 2005 39 7 687 695
48. Ceccarelli J., Delfino L., Zappia E., The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants International Journal of Cancer 2008 123 8 1770 1778